Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA-405) as a Booster in Chinese Adults & Older

NCT05897190 is registered in ClinicalTrials.gov with Argorna Pharmaceuticals Co., LTD as lead sponsor.

NCT NCT05897190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05897190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA-405) as a Booster in Chinese Adults & Older
Lead sponsor
Argorna Pharmaceuticals Co., LTD
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2022
Completion date
May 12, 2023
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2